We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and potentially other B-cell malignancies,” said ...

Investors in Nurix Therapeutics Inc (Symbol: NRIX) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a report issued on Tuesday,Benzinga reports. They currently have a $31.00 target price on ...

$NRIX insiders have traded $NRIX stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales. Here’s a ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like NX-5948.

Check the time stamp on this data. Updated AI-Generated Signals for Nurix Therapeutics Inc. (NRIX) available here: NRIX. Type ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seventeen brokerages that are presently covering the company, ...

Since it has a market capitalisation of US$1.4b, Nurix Therapeutics' US$107m in cash burn equates to about 7.9% of its market value. Given that is a rather small percentage, it would probably be ...

Nurix Therapeutics (NRIX) focuses on protein degradation in cancer treatment, with a current valuation of $1.4 billion and promising early-stage clinical data. NX-5948, a BTK degrader, shows high ...

SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...